infirst Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 1

infirst General Information

Description

Developer of enhanced medicines designed to improve treatment of common cough, inflammatory pain and chronic wounds. The company's medicines offer treatments for everyday ailments and bothersome symptoms, enabling healthcare practitioners to contribute to improved early medical intervention for everyday ailments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Central Point
  • 45 Beech Street
  • London EC2Y 8AD
  • England, United Kingdom
+44 020 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

infirst Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private 01-Apr-2021 000.00 Completed Generating Revenue
4. Later Stage VC 01-Nov-2019 000.00 Completed Generating Revenue
3. Early Stage VC 31-Mar-2017 00.000 000.00 000.00 Completed Generating Revenue
2. Early Stage VC 29-Jun-2015 $20.5M $52.3M 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 25-Mar-2013 $31.8M $31.8M 0000 Completed Generating Revenue
To view infirst’s complete valuation and funding history, request access »

infirst Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preferred Shares 00,000 00.000000 000.00 000.00 00 000.00 0.000
D Ordinary 000,000 00.000000 000.00 000.00 00 000.00 00.000
D Ordinary 000,000 00.000000 000.00 000.00 00 000.00 00.000
B Ordinary 00,000 00.000000 000.00 000.00 00 000.00 0.000
C Ordinary 00,000 00.000000 000.00 000.00 00 000.00 0.000
B Ordinary 279,901 $0.012348 $15.15 $15.15 1x $15.15 19.51%
A Ordinary 180,001 $0.012348 $15.15 $15.15 1x $15.15 12.54%
To view infirst’s complete cap table history, request access »

infirst Executive Team (11)

Name Title Board Seat Contact Info
Andrew Macmillen Managing Director & Board Member
Karen Stoner Director of Consumer Marketing & Drug Development
Karel Deckers Director of Manufacturing & Supplies
Martyn Buckley Director, Sales & Marketing
You’re viewing 4 of 11 executive team members. Get the full list »

infirst Board Members (11)

Name Representing Role Since
Alan Armstrong Self Board Member 000 0000
Andrew Macmillen infirst Managing Director & Board Member 000 0000
Gregory Stoloff Self Board Member 000 0000
Manfred Scheske Self Chairman 000 0000
Robin Lincoln Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

infirst Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
IW Capital PE/Buyout Minority 000 0000 000000 0
To view infirst’s complete investors history, request access »

infirst Subsidiaries (1)

Company Name Industry Location Founded
000000 Pharmaceuticals London, United Kingdom 0000
To view infirst’s complete subsidiaries history, request access »